Alchemical free energy calculation is the most accurate binding prediction routinely available, with reported accuracy approaching one kilocalorie per mole for well-behaved systems. It is also expensive, so it belongs at the point in lead optimisation where a wrong synthesis decision costs more than the calculation. We run relative and, where appropriate, absolute binding free energy calculations with careful perturbation mapping, convergence checking and validation against your existing measured data.
Before predicting untested compounds, we reproduce measured affinities for compounds you have already made, so the expected error on your system is known rather than quoted from a paper.
Network topology, cycle closure and intermediate states are planned to give redundancy, which both improves accuracy and exposes individual calculations that have failed.
Every transformation is assessed for phase-space overlap, hysteresis and convergence; edges that fail are rerun or reported as unreliable rather than averaged into the result.
We advise where FEP is worth its cost and where MM/GBSA suffices, because applying it indiscriminately wastes budget without improving decisions.
Computational predictions prioritise hypotheses; they do not independently establish binding, biological activity, therapeutic efficacy, safety or clinical validity. Performance depends on input quality, target class, the structural evidence available and the applicability domain of the selected methods. Scores used for ranking are comparative devices and should not be read as measured quantities. All deliverables are for research use only and are not intended for diagnostic or therapeutic use.
| Item | Specification | Notes |
|---|---|---|
| Transformations per study | 10–100 edges | Network size set by the design question |
| Typical turnaround | 3–6 weeks | Including validation and convergence checking |
| Reported accuracy | ≈1 kcal/mol | For well-behaved systems; system-dependent and stated per project |
| Prerequisite | Consistent binding mode | Series must share a confirmed pose |
We discuss the objective, the decision it supports and the data you hold. Nothing is quoted before we understand what the result has to answer.
We check that the data, target class and available structural evidence can support the proposed approach, and say plainly where they cannot.
Scope, methods, deliverables, timeline and price are confirmed in writing, together with the limitations we expect to report.
The analysis runs on pinned tool versions in a containerised environment, with quality checkpoints and method comparison where that is informative.
You receive the ranked results, the documented methods, the limitations and a proposed validation plan, plus support in interpreting them.
The failure modes that produce confident-looking results which do not survive the next experiment. Each one is designed against rather than discovered afterwards.
Illustrative of the shape this work takes. Details are generalised, no client or target is identified, and scope and outcome vary with the system in question.
Note: ICDMO delivers computational (in silico) services. Results prioritise hypotheses for testing; they do not by themselves establish binding, biological activity, efficacy or safety. All deliverables are for research use only and are not intended for diagnostic or therapeutic use. Downstream experimental work is scoped separately and executed through qualified partners.
Tell us about the target, the data you hold and the decision the result needs to support. A scientist reviews every enquiry and replies within one business day.
